This work proposes a comprehensive framework of biocatalytic continuous manufacturing of sitagliptin, the active pharmaceutical ingredient of the leading dipeptidyl peptidase-4 inhibitor antidiabetic drug. Continuous manufacturing has the advantages of quality consistency, reduced waste generation, and cost-effectiveness in comparison to batch processes. Furthermore, compared to traditional catalysts, biocatalysts have lighter environmental footprints. An end-to-end continuous manufacturing process is designed and the reaction kinetics of the biocatalytic reaction is determined according to the published data. Based on the steady-state model of a plug-flow microreactor, the optimal productivity is determined to be 2.6 x 10(-2)mol h(-1) using surrogate-based optimization. In addition, an assessment of the process' environmental impacts demonstrates its sustainability with a lower E-factor of 53 compared to 200 of traditional processes. A comprehensive techno-economic analysis has also been performed, validating the economic feasibility of this process with a net present value of $150 million over a 20 year time period. Therefore, this present work demonstrates the feasibility, sustainability, and economic competitiveness of the proposed process.

• National University of Singapore
• Massachusetts Institute of Technology (MIT) (MIT)

• API

1. API
2. biocatalysis
3. continuous pharmaceutical manufacturing
4. Environment
5. Research Article
6. Surrogate-based optimization
7. Techno-economic analysis